Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-month dose-level blinded study of CVT-301 inhaled levodopa in Parkinson's disease with OFF episodes
2015-005626-19Phase 3Completed
- Sponsor
- Civitas Therapeutics
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind, single-arm trial of levodopa inhalation powder in Parkinson's disease (PD), sponsored by Civitas Therapeutics. Primary endpoint: Pulmonary safety over 12 months. Started Apr 2016; status: completed.
02
Drugs
levodopa inhalation powder
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2015-005626-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005626-19.